Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Feb 10, 2026 | Press Releases

Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 RespondersNo Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation CohortsKing of...

Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

Jan 26, 2026 | Press Releases

Phio’s Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania–(Newsfile Corp. – January 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Jan 20, 2026 | Press Releases

Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable safety and tolerability at all dose escalations King of Prussia, Pennsylvania–(Newsfile Corp. – January 20, 2026) –...

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Jan 15, 2026 | Press Releases

Registration Link for Phio’s Presentation on Thursday, January 22 at 1:45 PM ETKing of Prussia, Pennsylvania–(Newsfile Corp. – January 15, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Dec 23, 2025 | Press Releases

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania–(Newsfile Corp. – December 23, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...